coreweave stock leads cathie wood's ark trades amid major gitlab sell-off

On November 24, 2025 ARK Investment Management materially reweighted ETF holdings, purchasing 437,345 shares of CoreWeave Inc (CRWV) for $31,335,769 via ARKK and adding 42,404 shares of CRISPR Therapeutics (CRSP) for $2,129,952, signaling continued emphasis on AI/cloud infrastructure and biotech. Concurrently ARK sold 646,911 shares of GitLab (GTLB) for $26,840,337 and reduced stakes in Iridium (IRDM) by 179,578 shares ($2,882,226) and Ibotta (IBTA) by 62,100 shares ($1,383,588), along with smaller trades in Circle (CRCL), Bullish (BLSH) and Reddit (RDDT). The activity highlights ARK’s sector rotation toward AI-related cloud plays and gene-editing exposure while trimming software and communications positions, actions that could influence the affected small- and mid-cap names but are unlikely to move broader markets.

Analysis

Market structure: ETF-driven reweights amplify price discovery in small/mid caps—beneficiaries are differentiated AI/cloud infrastructure providers that can translate demand into higher utilization and pricing power; losers are speculative software/comm names where liquidity withdrawal can force orderly price resets. Expect near-term dispersion: affected tickers' implied volatility to rise 20–60% over 3–10 trading days, while large-cap indices remain insulated.

Risk assessment: tail risks include export controls or chipset supply shocks that would compress cloud-GPU capacity (months) and stricter CRISPR/regulatory scrutiny that can reprice biotech by 30–70% around adverse outcomes (6–18 months). Immediate (days) risk is liquidity-driven spillover; short-term (weeks/months) is earnings/GPU availability and trial readouts; long-term (quarters/years) is secular adoption of AI infra and gene editing.

Trade implications: prioritize liquidity-aware positions sized 1–3% AUM per idea. Favor long exposure to resilient AI infra providers with visible utilization metrics and buy-protective option structures; for software/comm names use short-duration puts or pair shorts funded by longs in infra names to exploit ARK-driven rotation over 1–3 months. Scale entries across 2–4 tranches over 2–8 weeks to manage execution and IV risk.

Contrarian angles: consensus overweights the signal as permanent — crowding risk is high and capacity/earnings execution will determine winners, not flows. Historical ARK rotations show >30% mean reversion when moves rely on sentiment, so avoid full conviction until fundamentals (GPU utilization, CRSP trial milestones) validate price action; unintended consequence is higher trading costs and bid-ask dislocation in thin names.

Key Decisions for Investors

• Establish a 2% AUM long in CRWV (or nearest tradable AI infra proxy) sized in 2 tranches: 50% within 5 trading days, 50% on a 5–15% pullback. Target +35–50% over 3–6 months; stop-loss at -15% from entry.
• Allocate a 1–1.5% AUM tactical long to CRSP with 12–18 month horizon ahead of clinical/FDA catalysts; hedge binary downside with a 12-month 30% OTM buy-write or protective put limiting drawdown to ~20% of position cost.
• Implement a pair trade: long CRWV (1% AUM) / short GTLB (1% AUM) notional, short via 3-month put spread on GTLB (buy 30% OTM put, sell 15% OTM put) to cap cost. Rebalance weekly for 4–8 weeks or until relative move >20%.
• Reduce concentrated small-/mid-cap software exposure by 25–50% within 10 trading days; redeploy proceeds into AI infra (CRWV/GOOGL cloud exposure) and defensive cash-equivalents to lower portfolio beta by 0.2–0.4 over next quarter.
• Monitor specific triggers: GPU vendor supply/pricing announcements and CoreWeave utilization reports over the next 30–90 days, and CRSP clinical readouts/FDA calendar over next 6–18 months — if negative, tighten stops or close positions within 48 hours of definitive adverse news.